Amin RH, Mathews ST., Camp HS, Ding L, Leff T. Selective activation of PPAR␥ in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am J Physiol Endocrinol Metab 298: E28 -E37, 2010. First published October 20, 2009 doi:10.1152/ajpendo.00446.2009.-The nuclear receptor peroxisome proliferator-activated receptor (PPAR)␥ plays a key role in regulating whole body glucose homeostasis and insulin sensitivity. Although it is expressed most highly in adipose, it is also present at lower levels in many tissues, including skeletal muscle. The role muscle PPAR␥ plays in metabolic regulation and in mediating the antidiabetic effects of the thiazolidinediones is not understood. The goal of this work was to examine the molecular and physiological effects of PPAR␥ activation in muscle cells. We found that pharmacological activation of PPAR␥ in primary cultured myocytes, and genetic activation of muscle PPAR␥ in muscle tissue of transgenic mice, induced the production of adiponectin directly from muscle cells. This muscle-produced adiponectin was functional and capable of stimulating adiponectin signaling in myocytes. In addition, elevated skeletal muscle PPAR␥ activity in transgenic mice provided a significant protection from high-fat diet-induced insulin resistance and associated changes in muscle phenotype, including reduced myocyte lipid content and an increase in the proportion of oxidative muscle fiber types. Our findings demonstrate that PPAR␥ activation in skeletal muscle can have a significant protective effect on whole body glucose homeostasis and insulin resistance and that myocytes can produce and secrete functional adiponectin in a PPAR␥-dependent manner. We propose that activation of PPAR␥ in myocytes induces a local production of adiponectin that acts on muscle tissue to improve insulin sensitivity. diabetes; peroxisome proliferator-activated receptor-␥; adiponectin; skeletal muscle; transgenic mice ACTIVATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-␥ (PPAR␥) by thiazolidinedione (TZD) treatment causes profound metabolic changes that lead to improvements in whole body insulin sensitivity and glucose homeostasis in diabetic individuals (9,17,23,32). Although one of the major metabolic effects of PPAR␥ activation is to improve skeletal muscle insulin sensitivity, the degree to which these effects are mediated by PPAR␥ resident in muscle tissue is not clearly understood. The level of PPAR␥ in muscle is relatively low compared with adipose tissue (3, 26), and many of the known effects of TZDs on muscle could potentially be the indirect result of PPAR␥ activation in adipose tissue (35). However, several lines of evidence indicate a specific metabolic role for muscle PPAR␥, suggesting that it contributes directly to the antidiabetic effects of the TZDs.The strongest suggestion of a direct metabolic role for muscle PPAR␥ comes from a study using a muscle-specific PPAR␥ knockout line. Hevener et al. (19) found that mice without skeletal muscle PPAR␥...